Drug Approval | September 30, 2022
USFDA inspects Zydus Lifesciences Ahmedabad SEZ facility
The company will address the observations within a stipulated timeline working with the regulators
The company will address the observations within a stipulated timeline working with the regulators
Sud has more than 32 years of work experience with different companies like Clivient, Jubilant Life Sciences, Piramal Enterprises, Parabolic Drugs, Orchid Chemicals and Pharmaceuticals, Ranbaxy Labs, and Lupin
MonoFerric, iron isomaltoside 1000 solution for injection/infusion, is a rapid, single dose IV iron developed to reduce the number of infusions
The MOU provides for assistance in the form of efficient working Capital Management, development and commercialisation of new products, logistic supply chain management support etc.
The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
The company has reported total income of Rs. 186.97 crores during the period ended June 30, 2022.
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
Subscribe To Our Newsletter & Stay Updated
